These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11964902)

  • 1. Hyperlactatemia syndromes in people with HIV infection.
    John M; Mallal S
    Curr Opin Infect Dis; 2002 Feb; 15(1):23-9. PubMed ID: 11964902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors.
    Brinkman K
    Clin Infect Dis; 2000 Jul; 31(1):167-9. PubMed ID: 10913416
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens.
    Lonergan JT; Behling C; Pfander H; Hassanein TI; Mathews WC
    Clin Infect Dis; 2000 Jul; 31(1):162-6. PubMed ID: 10913415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.
    John M; Moore CB; James IR; Nolan D; Upton RP; McKinnon EJ; Mallal SA
    AIDS; 2001 Apr; 15(6):717-23. PubMed ID: 11371686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors.
    Claessens YE; Chiche JD; Mira JP; Cariou A
    Crit Care; 2003 Jun; 7(3):226-32. PubMed ID: 12793872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
    Calza L; Manfredi R; Chiodo F
    Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors].
    Pedrol E; Ribell M; Deig E; Villà Mdel C; Miró O; Garrabou G; Soler A
    Med Clin (Barc); 2005 Jul; 125(6):201-4. PubMed ID: 16022831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
    Lonergan JT; Barber RE; Mathews WC
    AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment.
    Noguera A; Fortuny C; Sanchez E; Artuch R; Vilaseca MA; Muñoz-Almagro C; Pou J; Jiménez R
    Pediatr Infect Dis J; 2003 Sep; 22(9):778-82. PubMed ID: 14506367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
    Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
    Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient.
    Bleeker-Rovers CP; Kadir SW; van Leusen R; Richter C
    Neth J Med; 2000 Nov; 57(5):190-3. PubMed ID: 11063865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients.
    Marceau G; Sapin V; Jacomet C; Ughetto S; Cormerais L; Regagnon C; Dastugue B; Peigue-Lafeuille H; Beytout J; Laurichesse H
    Clin Chem; 2003 Jul; 49(7):1154-62. PubMed ID: 12816913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactic acidosis related to nucleoside therapy in HIV-infected patients.
    Falcó V; Crespo M; Ribera E
    Expert Opin Pharmacother; 2003 Aug; 4(8):1321-9. PubMed ID: 12877640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F; García-Benayas T; José de la Cruz J; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(1):11-9. PubMed ID: 12577192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlactataemia syndromes associated with HIV therapy.
    Ogedegbe AE; Thomas DL; Diehl AM
    Lancet Infect Dis; 2003 Jun; 3(6):329-37. PubMed ID: 12781504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hyperlactatemia: no need for routine lactate measurements.
    Brinkman K
    AIDS; 2001 Apr; 15(6):795-7. PubMed ID: 11371695
    [No Abstract]   [Full Text] [Related]  

  • 19. Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis.
    Springer SA; Altice FL
    Clin Infect Dis; 2003 Jun; 36(12):e162-4. PubMed ID: 12802782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.